High-Value Federal Grants ($5M+) — July 22, 2026

This recent (2023) full-and-open competition win provides a multi-year revenue stream of ~$28.7M/year, with $33M already outlaid, signaling stable cash flow from a civilian agency with consistent public health funding.

The contract ended in November 2019, meaning the $182.7M obligation is fully recognized; investors cannot rely on this for current or future revenue, and the company's current market position is unclear.

True North Communications' time-and-materials pricing on the $95.8M FDA contract caps profit margins, and campaign performance could affect future modifications or extensions.

Ares Technical Services has no current revenue from the $182.7M NASA contract, creating a revenue gap unless new awards are secured; the company's dependence on this single past award is a concentration risk.

True North Communications' FDA win demonstrates ability to compete in full-and-open civilian contracts; similar opportunities exist at HHS, CDC, or other agencies for public health campaigns.

Ares Technical Services' past NASA contract positions it for future space mission assurance work, especially as NASA increases R&D spending; new awards could restore revenue streams.

The $95.8M FDA contract to True North Communications highlights sustained investment in public health messaging, a non-defense but stable budget area.

The $182.7M NASA contract to Ares Technical Services, though completed, underscores long-term NASA investment in safety and mission assurance R&D.

{"entity" => "True North Communications Inc", "reason" => "Recent $95.8M FDA contract provides multi-year revenue; watch for modifications or extensions.", "trigger" => "FDA budget announcements for FY2024-2026; contract modifications beyond December 2026"}

{"entity" => "Ares Technical Services Corporation", "reason" => "Past $182.7M NASA contract is completed; need new awards to assess current revenue.", "trigger" => "New NASA or other agency contract awards; small business set-aside policy changes"}